Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Tiziana Life Sciences Plc ADR (NQ: TLSA )

3.310 -0.180 (-5.16%)
Streaming Delayed Price Updated: 2:29 PM EDT, Sep 28, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 184,909
Open 3.580
Bid (Size) 3.310 (1)
Ask (Size) 3.370 (1)
Prev. Close 3.490
Today's Range 3.310 - 3.590
52wk Range 1.540 - 16.79
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Tiziana Life Sciences Interview to Air on Bloomberg International on The RedChip Money Report
From GlobeNewswire News Releases
Tiziana Life Sciences plc: Publication of Research Note
From GlobeNewswire News Releases

Performance

YTD
+16.80%
+16.80%
1 Month
-10.05%
-10.05%
3 Month
-50.08%
-50.08%
6 Month
+77.96%
+77.96%
1 Year
-46.27%
-46.27%

More News

Read More
Tiziana Life Sciences plc to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil
From GlobeNewswire News Releases
Tiziana Life Sciences Announces Planned Spin Out of StemPrintER into a New Publicly Listed Company, Accustem Sciences
From GlobeNewswire News Releases
Tiziana Life Sciences Plc ("Tiziana" or the "Company") - Demerger of StemPrintER and Distribution in Specie
From GlobeNewswire News Releases
Tiziana Life Sciences Clarifies Reason for Filing an Amended ADS Registration Statement
From GlobeNewswire News Releases
Tiziana Life Sciences CEO Updates Shareholders on its Patent Portfolio, Clinical Pipeline, and Strategy in an Exclusive Interview
From GlobeNewswire News Releases
Tiziana Granted a Patent on Methods and Use of Anti-IL-6/IL-6 receptor Monoclonal Antibodies as Prophylactic and Therapeutic Interventions for COVID-19 and other pulmonary diseases
From GlobeNewswire News Releases
Tiziana Granted a Patent on the Use of Milciclib in Combination with Tyrosine Kinase Inhibitors for Treatment of Hepatocellular Carcinoma and other Cancers
From GlobeNewswire News Releases
Tiziana is Pleased to Retain Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board for an Additional Three-Year Term
From GlobeNewswire News Releases
The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO
Tags PTGX News LLY
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.